Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September:
- 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET);
- Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and
- Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 1:05 p.m. ET.
The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Julie Normart (media) Pure Communications 415-946-1087 [email protected]
